AstraZeneca Could Seek New Indication For Iressa In Europe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February